Hugel Cash Ratio
Cash Ratio of Hugel (145020.KQ) as of Oct 23, 2026.
Get this data via API
Financial Data API
Cash Ratio
0.00
Last updated:
Cash Ratio of Hugel is 2025 0.00 . Cash Ratio of Hugel was 2024 39.19 . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Hugel Stock analysis
What does Hugel do? Hugel Inc generates revenue by manufacturing and selling biopharmaceuticals based on clostridium botulinum, with products distributed in both domestic and overseas markets. The company’s portfolio includes botulinum toxins available in 50 unit types, 100 unit types, and 200unit types for treating benign essential blepharospasm and improving moderate to severe glabellar lines. Additionally, the firm offers hyaluronic acid fillers designed for the temporary removal of facial wrinkles, specifically the chaeum premium No.1, the chaeum premium No.2, the chaeum premium No.3m, the chaeum premium No.4, the chaeum MID 20A, the chaeum DEEP 20A, the chaeum SUB-Q 20A, and the chaeum VOLUS 20A. Beyond these medical aesthetics, the business also sells wellages, blue roses, and other cosmetics to its customer base. Hugel is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Hugel stock
On Eulerpool you can find the complete historical development of Cash Ratio Hugel since 2006 – with annual values, charts, and detailed analysis.
The Cash Ratio is the most conservative liquidity metric, comparing only cash and equivalents to current liabilities.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Ratio's Hugel with sector peers and the industry average to assess whether it is attractive.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Leverage — Hugel
All Key Metrics — Hugel
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth